Care Pathway Sample Clauses

Care Pathway. A full description of the screening pathway is given below, along with a diagram of the pathway (figure1). The screening pathway consists of the following: • Identify population - the eligible population is identified through maternity antenatal care services. For Down’s syndrome screening, the eligible population is women with xxxxxxxxx and twin pregnancies <20+0 weeks of pregnancy confirmed by ultrasound scan and for Xxxxxxx’ and Patau’s syndromes screening using biochemical markers the eligible population are women with xxxxxxxxx and twin pregnancies ≤ 14+1 weeks of pregnancy confirmed by ultrasound scan • Inform - during the first contact or booking visit with the midwife, verbal and written information about the dating scan and screening is given to the woman (using the NHS Screening Programmes booklet ‘Screening Tests for You and Your Baby’) to enable her to make an informed choice and screening offered • Offer - the offer of screening and subsequent acceptance or decline should be documented • Test – • combined screening is performed between 10+0 to 14+1 weeks gestation. The maternal serum sample can be taken between 10+0 to 14+1 weeks gestation and the nuchal translucency measured between 11+2 and 14+1 weeks. For purposes of screening the eligibility for first trimester screening using the combined test is a crown rump length (CRL) measurement of 45.0mm – 84.0mm • for women between 14+2 and 20+0 weeks, the quadruple test is performed for the assessment of risk for Down’s syndrome only in women with a xxxxxxxxx and twin pregnancy. The recommended screening strategy for Xxxxxxx’ and Patau’s syndrome for women who present for care ≥14+2 but between 18+0 and 23+0 weeks gestation is the fetal anomaly scan • arrangements for the sequencing of the ultrasound component (i.e. CRL/NT) and the collection of the maternal blood sample should be defined by local protocol and are the responsibility of the Provider. Where screening in the first trimester using the combined screening strategy is accepted, the biochemical component of the test must be completed regardless of the measurement of the nuchal Translucency. Where a nuchal translucency measurement of ≥3.5 mm is recorded, referral should not be delayed to await biochemistry information but results should be forwarded to the clinician as soon as they are available to support discussion of further investigative options with the woman • a local failsafe protocol must be in place to ensure that all women who ac...
Sample 1
AutoNDA by SimpleDocs
Care Pathway. An updated care pathway for diabetic eye screening can be viewed on the link below. xxxxx://xxx.xxx.xx/government/uploads/system/uploads/attachment_data/file/ 493991/DES_-_revision_2.pdf
Sample 1
Care Pathway. The care pathways for patients are as follows:  New referrals from acute neurology or neurosurgery service, secondary care paediatric services, or, occasionally, primary care  Assessment in the in-patient or out-patient setting and active treatment or monitoring of the condition commenced.  Active treatment as an in-patient or in the community, supported by the specialist neurorehabilitation team.  A small number of cases of children with rare conditions (e.g. ASI) might be referred from the regional paediatric neurorehabilitation service to a supra- regional paediatric neurorehabilitation unit or managed on a shared- care basis.  Discharge from in-patient or out-patient support by the specialist neurorehabilitation service to the local paediatric service and community disability team.  There are various pathways for long-term care:  Condition resolves – discharge from primary care  Condition stable – shared management with secondary care or management entirely by secondary care  Condition complex and long term – shared management with secondary care but with tertiary service continuing to play a significant role in an outreach capacity.  Patients discharged to secondary or primary care who later develop problems related to their neurological condition can be re-referred to the tertiary specialist neurorehabilitation service for assessment and possibly further treatment.  Cases will be accepted if they meet the acceptance criteria (see below).  For those with complex life-long conditions and those still requiring neurorehabilitation services in adult life, transitional care arrangements will be made appropriate local adult services. Transition to adult services will occur between ages 16-19 years, according to patient and parent preference, local arrangements and the availability of suitable services. Packages of care Patients referred to the tertiary specialist service, as an in-patient or out patient, would be assessed and, if appropriate, then offered a package of treatment either as an in-patient or out-patient.
Sample 1
Care Pathway. 7.1 Patients will be signposted to the service by other health care professionals involved in their care.
Sample 1
Care Pathway. The care pathway follows that: • the eligible population is identified through the issuing of an NHS number at birth or registration with a GP practice for babies born abroad • registered health care professionals check antenatal results and family history. Ideally all antenatal results obtained from antenatal SCT screening are included on the blood spot card • registered health care professionals provide written information (ideally before birth) and take verbal consent • screening is offered to unscreened babies who move into a local area under a year of age. Health visiting services (or agreed alternative) are responsible for offering screening to parents of babies with no documented screening results in English. The CHRD who record the arrival of a baby should alert the HV to unscreened babies. GPs should ensure CHRD are informed of the babies they register • samples are taken on day 5 (day of birth is day 0), in accordance with Guidelines for Newborn Blood Spot Sampling (2016), and sent on the day of sampling to the appropriate newborn screening laboratory. Records are kept of all tests including those declined • additional tests are offered to babies born preterm and babies at risk of blood transfusion and if required by a screening protocol to achieve a conclusive result. For SCT please refer to Service specification No. 18: NHS sickle cell and thalassaemia screening programme • the Newborn screening laboratory tests the sample according to national policy and reports the results to the Child Health Records Department and the Newborn Blood Spot Failsafe Solution. This can result in one of five outcomes: • carrier: healthcare professional informs parents of results • inconclusive result: additional sample required • avoidable repeat test: additional sample required, for example, insufficient blood, missing/inaccurate details on the card • condition not suspected: parents are informed of the result • condition suspected: immediate clinical referral to a specialist initiated by the laboratory and parents informed of the result, by the specialist service • maternity care providers ensure all babies they are responsible for are offered screening by using the Newborn Blood Spot Failsafe Solution • Child Health Records Departments maintain a list of the eligible population to provide a failsafe check to identify untested babies, to monitor coverage and to send results to health visiting services (or agreed alternative) and parents according to national pol...
Sample 1
Care Pathway. Preventx will send electronic notifications to patients as soon as their prescription has been dispatched. It is the providers or screening offices responsibility to book in patients who have requested a LARC appointment.
Sample 1
Care Pathway. A new screening pathway diagram will be here based on the Map of Medicine pathway – link below. xxxxx://xxx.xxx.xx/government/uploads/system/uploads/attachment_data/file/ 440075/Diabetic_eye_screening.pdf
Sample 1
AutoNDA by SimpleDocs
Care Pathway. (s) Following initial assessment patients follow planed pathways of care according to need, the diagnosis and agreed treatment plan. 3.2 Staffing All staff and volunteers employed by Keech Hospice will fulfill the following criteria: • Qualified staff are registered with their relevant professional body • Qualified staff are required to keep an up to date continuing professional development (CPD) portfolio • Qualified staff meet knowledge and skills competencies appropriate for the post • All staff are required to attend mandatory training including Health & Safety, Safeguarding and Risk Management. • Satisfactory enhanced CRB checks completed. 3.3
Sample 1
Care Pathway. An updated care pathway for diabetic eye screening can be viewed on the link below. xxxxx://xxx.xxx.xx/government/uploads/system/uploads/attachment_data/file/493991/ DES_-_revision_2.pdf This pathway does not currently include 2 yearly screening intervals 3.3 Description of the screening pathway‌‌ NDESP is based on the policies developed by the NHS Screening Programmes. The screening procedure is divided into the following stages: • identification • invitation • inform • test • diagnose • referral for treatment/ intervention • surveillance • monitor outcomes In accordance with NHS Screening Programmes’ standards and protocols the provider shall follow the care pathway for diabetic eye screening. Regardless of the model of delivery e.g. technician /optometry based/ fixed camera/ mobile camera the pathway as specified must be followed The population eligible for screening is: all persons diagnosed with diabetes mellitus (excluding gestational diabetes) aged 12 or over who have light perception or better in at least one eye. Screening should be offered to the eligible population unless they have been excluded or suspended according to national guidance – NDESP: Exclusions, Suspensions and Management of Ungradables xxxxx://xxx.xxx.xx/government/publications/diabetic-eye-screening-screening-exclusions- and-suspensions-and-managing-ungradable-images
Sample 1

Related to Care Pathway

  • Surgery Services and Mastectomy Related Treatment This plan provides benefits for mastectomy surgery and mastectomy-related services in accordance with the Women’s Health and Cancer Rights Act of 1998 and Rhode Island General Law 27-20-29 et seq. For the member receiving mastectomy-related benefits, coverage will be provided in a manner determined in consultation with the attending physician, physician assistant, or an advance practice registered nurse and the patient, for: • all stages of reconstruction of the breast on which the mastectomy was performed; • surgery and reconstruction of the other breast to produce a symmetrical appearance; • prostheses; and • treatment of physical complications at all stages of the mastectomy, including lymphedema. See the Summary of Medical Benefits for the amount you pay.

  • Hospice g. Individuals whose permanent residence and principal work location are outside the State of Minnesota and outside of the service areas of the health plans participating in Advantage. If these individuals use the plan administrator’s national preferred provider organization in their area, services will be covered at Benefit Level Two. If a national preferred provider is not available in their area, services will be covered at Benefit Level Two through any other provider available in their area. If the national preferred provider organization is available but not used, benefits will be paid at the POS level described in paragraph “i” below. All terms and conditions outlined in the Summary of Benefits will apply.

  • Virus detection You will be responsible for the installation and proper use of any virus detection/scanning program we require from time to time.

  • Medication Assisted Treatment This plan covers medication assisted treatment for substance use disorders, including methadone maintenance treatment. Please see the Summary of Medical Benefits for specific copayments for these services.

  • Psychotherapist-Patient Privilege The information disclosed by Patient, as well as any records created, is subject to the psychotherapist-patient privilege. The psychotherapist-patient privilege results from the special relationship between Therapist and Patient in the eyes of the law. It is akin to the attorney-client privilege or the doctor-patient privilege. Typi- cally, the patient is the holder of the psychotherapist-patient privilege. If Therapist received a subpoena for records, deposition testimony, or testimony in a court of law, Therapist will assert the psychotherapist-patient privilege on Patient’s behalf until instructed, in writing, to do otherwise by Patient or Patient’s representative. Patient should be aware that he/she might be waiving the psychotherapist-patient privilege if he/she makes his/her mental or emotional state an issue in a legal proceeding. Patient should address any concerns he/she might have regarding the psychotherapist-patient privilege with his/her attorney. Fee and Fee Arrangements The usual and customary fee for service is $100.00 per 50-minute session. Sessions longer than 50-minutes are charged for the additional time pro rata. Therapist reserve the right to periodically adjust this fee. Patient will be notified of any fee adjustment in advance. In addition, this fee may be adjusted by contract with in- surance companies, managed care organizations, or other third-party payers, or by agreement with Therapist. From time-to-time, Therapist may engage in telephone contact with Patient for purposes other than sched- uling sessions. Patient is responsible for payment of the agreed upon fee (on a pro rata basis) for any tele- phone calls longer than ten minutes. In addition, from time-to-time, Therapist may engage in telephone con- tact with third parties at Patient’s request and with Patient’s advance written authorization. Patient is respon- sible for payment of the agreed upon fee (on a pro rata basis) for any telephone calls longer than ten minutes. Patients are expected to pay for services at the time services are rendered. Therapist accepts cash, or major credit cards.

  • Treatment Program Testing The Employer may request or require an employee to undergo drug and alcohol testing if the employee has been referred by the employer for chemical dependency treatment or evaluation or is participating in a chemical dependency treatment program under an employee benefit plan, in which case the employee may be requested or required to undergo drug or alcohol testing without prior notice during the evaluation or treatment period and for a period of up to two years following completion of any prescribed chemical dependency treatment program.

  • Interoperability To the extent required by applicable law, Cisco shall provide You with the interface information needed to achieve interoperability between the Software and another independently created program. Cisco will provide this interface information at Your written request after you pay Cisco’s licensing fees (if any). You will keep this information in strict confidence and strictly follow any applicable terms and conditions upon which Cisco makes such information available.

  • Industry Troubleshooter Where a difference arises between the parties relating to the dismissal, discipline, or suspension of an employee, or to the interpretation, application, operation, or alleged violation of this Agreement, including any question as to whether a matter is arbitrable, during the term of the Collective Agreement, Xxxxx XxXxxxxxxx, Xxxx Xxxxxx, Xxxxx Xxxxxxxx, or a substitute agreed to by the parties, shall at the request of either party:

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Preventive Care and Early Detection Services This plan covers, early detection services, preventive care services, and immunizations or vaccinations in accordance with state and federal law, including the Affordable Care Act (ACA), as set forth below and in accordance with the guidelines of the following resources: • services that have an A or B rating in the current recommendations of the U.S. Preventative Services Task Force (USPSTF); • immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention; • preventive care and screenings for infants, children, and adolescents as outlined in the comprehensive guidelines supported by the Health Resources and Services Administration (HRSA); or • preventive care and screenings for women as outlined in the comprehensive guidelines as supported by HRSA. Covered early detection services, preventive care services and adult and pediatric immunizations or vaccinations are based on the most currently available guidelines and are subject to change. The amount you pay for preventive services will be different from the amount you pay for diagnostic procedures and non-preventive services. See the Summary of Medical Benefits and the Summary of Pharmacy Benefits for more information about the amount you pay. Preventive Office Visits This plan covers the following preventive office visits. • Annual preventive visit - one (1) routine physical examination per plan year per member age 36 months and older; • Pediatric preventive office and clinic visits from birth to 35 months - 11 visits; • Well Woman annual preventive visit - one (1) routine gynecological examination per plan year per female member.

Time is Money Join Law Insider Premium to draft better contracts faster.